1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/18 12:38:22 pm
142.425 USD   -2.81%
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen Canada Announces Availability of PADCEV« to Treat Advanced Bladder Cancer

01/25/2022 | 08:30am EDT

Seagen Canada announced the commercial availability of PADCEV® (enfortumab vedotin) for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy. Bladder cancer affects an estimated 12,000 Canadians each year making it the fifth leading cancer diagnosis in Canada.4 Bladder cancer is a disease where cancer cells form in the tissues of the bladder5. Urothelial cancer is the most common type of bladder cancer, accounting for about 90% of all cases.6 The advanced stages of urothelial cancer are often referred to as locally advanced or metastatic.7 Although some locally advanced or metastatic bladder cancer will stop growing, shrink, or even disappear in response to current treatment options, the cancer almost always returns and grows aggressively, shortening life expectancy. The Heath Canada approval of PADCEV was based on an open–label, randomized, phase 3, multicenter study (EV 301) that enrolled 608 patients (including 52 Canadians) with unresectable locally advanced or metastatic urothelial cancer who received prior treatment with a platinum–containing chemotherapy and PD–1 or PD–L1 inhibitor, a type of immunotherapy. At median follow-up of approximately 11 months, compared with chemotherapy, enfortumab vedotin met its primary endpoint and improved overall survival (OS) by almost four months (median 12.88 months versus 8.97 months). A recent Seagen Canada survey gauging Canadian's knowledge of bladder cancer, conducted by Leger Research, found that many Canadians have limited knowledge as it relates to the condition. Key survey learnings included: less than one third (31%) of respondents knew smoking was a risk factor for bladder cancer; most respondents (89%) are unaware that bladder cancer has one of the highest recurrence rates among all cancers; the majority of respondents (60%) did not know that certain occupations, such as painter, plumber or firefighter, can pose a higher risk for developing bladder cancer; and only four-in-ten (42%) respondents know that bladder cancer is a treatable cancer, relative to some other forms of cancer.


ę S&P Capital IQ 2022
All news about SEAGEN INC.
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
05/16INSIDER SELL : Seagen
MT
05/16SEAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
05/16Seagen's President, CEO Clay Siegall Resigns Amid Investigation
MT
05/16Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
BU
05/16Seagen Announces Resignation of Clay Siegall as CEO
CI
05/09SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close
MT
05/09SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 792 M - -
Net income 2022 -648 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -42,0x
Yield 2022 -
Capitalization 26 976 M 26 976 M -
EV / Sales 2022 14,2x
EV / Sales 2023 10,1x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 146,55 $
Average target price 160,17 $
Spread / Average Target 9,29%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Marc E. Lippman Independent Director
Felix James Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-5.21%26 976
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
ICON PUBLIC LIMITED COMPANY-32.47%17 002
ALNYLAM PHARMACEUTICALS, INC.-26.37%15 622